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Abstract: Solanum nudum Dunal steroids have been reported as being antimalarial 
compounds; however, their concentration in plants is low, meaning that the species could 
be threatened by over-harvesting for this purpose. Swern oxidation was used for 
hemisynthesis of diosgenone (one of the most active steroidal sapogenin diosgenin 
compounds). Eighteen structural analogues were prepared; three of them were found to be 
more active than diosgenone (IC50 27.9 μM vs. 10.1 μM, 2.9 μM and 11.3 μM). The 
presence of a 4-en-3-one grouping in the A-ring of the compounds seems to be 
indispensable for antiplasmodial activity; progesterone (having the same functional group 
in the steroid A-ring) has also displayed antiplasmodial activity. Quantitative correlations 
between molecular structure and bioactivity were thus explored in diosgenone and several 
derivatives using well-established 3D-QSAR techniques. The models showed that 
combining electrostatic (70%) and steric (30%) fields can explain most variance regarding 
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compound activity. Malarial parasitemia in mice became reduced by oral administration of 
two diosgenone derivatives.  
Keywords: malaria; natural product; steroid; diosgenone; structural analogue; animal model 
 
1. Introduction 
Malaria is a parasitic disease which is responsible for about one million deaths annually [1]; its high 
morbidity and mortality affects more than 106 countries, in which there were nearly 216 million 
episodes of malaria in 2010 alone. There is a compelling need to look for new strategies for treating 
malaria [2] considering the above and first-line drugs’ high failure rates (i.e., chloroquine, 
amodiaquine, sulfadoxine/pyrimethamine) [3]; therefore compounds having new mechanisms of action 
and less (or no) adverse effects are urgently needed. It is well-recognized that natural products 
represent a source of new drugs and several properties, including flavonoids, alkaloids (i.e., quinine), 
coumarins, quinines, terpenes and lactones (i.e., artemisinins) [4]. 
It has been reported that diosgenone (2) and several steroid derivatives isolated from Solanum 
nudum Dunal having a 4-en-3-one system, such as SN-1 (3) and SN-2 (4) (Figure 1), have 
antiplasmodial activity against FcB-2 chloroquine-resistant strains [5–7]. Only a few reports 
concerning antiplasmodial activity of steroids could be found in the literature, in spite of the fact that 
some steroidal alkaloids are active against malaria [8]. 
Figure 1. Structure of diosgenin and diosgenone, SN-1 and SN-2 S. nudum sapogenin. 
 
S. nudum steroidal compounds’ antiplasmodial activity and their lack of mutagenicity, 
clastogenicity [9,10] and cytotoxicity [11] have substantiated this plant’s potential use in anti-malarial 
medication and encouraged attempts to search for new pharmacophores and more active compounds 
than diosgenone. The presence of an enone structure in the A-ring and a spirostane in the E-ring were 
thus select to generate a series of derivatives as potential antimalarial products. However, diosgenone 
is only present in the plant in terms of a few milligrams per kilogram of plant material; obtaining it by 
hemisynthesis from commercial diosgenin was thus deemed reasonably logical and would also lead to 
obtaining a further series of derivatives. 
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Natural compounds’ synthesis is complex due to the presence of several functional groups in the 
side chain and D-ring; diosgenone hemisynthesis from diosgenin was thus a sound alternative for 
determining its structure-activity relationship and carrying out studies of its in vivo activity, absorption 
and toxicity. Since the synthesis of other compounds involving only diosgenone A- and B-rings is 
expected to yield new types of antimalarial substances, diosgenone and some diosgenin steroid 
derivatives were obtained and their antiplasmodial potential determined. 
A preliminary structure-activity relationship was established and quantitative structure-activity 
relationship (QSAR) studies determined correlations between molecular structure and biological 
activity. This involved using 3D quantitative structure activity relationship (3D-QSAR) [12], a  
well-established drug design methodology providing information regarding statistical correlations 
between molecular structure descriptors and experimentally-measured bioactivity [13]. The partial 
linear squares (PLS) [14] algorithm provided a solid mathematical background for 3D-QSAR for 
statistically-significant models having acceptable predictive capability, ensured by very conservative 
cross-validation testing. This chemometric tool has been used for studying the leishmanicidal activity 
of some acnistins and withajardins [15]. 3D-QSAR models have provided detailed structural 
information about the factors best explaining the variance observed in experimental bioactivity data. 
2. Results and Discussion 
2.1. Chemical Transformation 
Diosgenone (2) was obtained from diosgenin (1) through a Swern oxidation [16]; the double bond 
was then isomerized with oxalic acid in a two-step procedure in a one-pot reaction (84%). This type of 
reaction has been reported for other compounds and resembles the primary transformation of steroidal 
sapogenins into progesterone [17]. 
Nine diosgenone analogues (compounds 7–15) and five analogues of diosgenin (compounds 16–20) 
were synthesized (Scheme 1). These fourteen derivatives were synthesized through several structural 
modifications to the A- and B-rings and in the diosgenin (1) and diosgenone (2) spiroketal system. 
Derivatives 7 and 8 were prepared by adding Grignard reagents (Me, Bn, Scheme 2) to compound 
2; compound 9 was produced by adding p-toluenesulfonic hydrazine. Treating the double bond with 
H2O2 produced compound 10 as a non-isolable 2:1 mixture (according to NMR spectra) of  and  
-epoxides. Hydrogenation in Pd/C and reduction with NaBH4 yielded compounds 11 and 13. 
Compound 12 was obtained from 2 with an excess of 2,3-dichloro-5,6-dicyanobenzoquinone (DDQ) in 
refluxing toluene, while Oxone® (potassium peroxymonosulfate) treatment of 2 in basic media 
produced 14, in turn transformed into 15 with TMSI. 
Five derivatives were also prepared from diosgenin 1; Compound 16 was obtained with acetic 
anhydride and epoxidation with H2O2 produced compound 17, while treatment with excess PCC 
produced 18 and a Clemmensen reduction yielded 19. Derivative 20 was produced after treating 1 with 
acetic anhydride and zinc chloride [18] (Scheme 2). 
Four other derivatives were prepared from compound SN-1 (3). Compound 21 was obtained by 
Swern oxidation, 22 through a hydrogenolysis reaction with Pd/C as catalyst, while 23 was the product 
of acetylation with excess acetic anhydride and 24 was obtained after reduction with NaBH4 in 
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methanol at room temperature, unfortunately it was not possible to assign the diastereoisomeric ratio 
(Scheme 3). Derivative 25 was produced from SN-2 (4) with another Swern oxidation. 
Scheme 1. Diosgenone (2) and derivatives 7–15 prepared by modifications made in the A- 
and B-rings and the spiroketal system. 
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Scheme 2. Diosgenin derivatives 16–20 obtained by modifications made to the A- and  
B-rings. Diosgenin (1). 
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Scheme 3. SN-1 derivatives 21–24 produced by modifications made to the side chain and 
A-ring. SN-1 (3). 
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2.2. Antiplasmodial Activity  
The anti-plasmodium activity of 25 derivatives, including progesterone (5) and 17-OH progesterone 
(6), was assayed in two P. falciparum strains (Table 1); this analysis was based on the dose inhibiting 
50% of parasite growth (IC50) expressed in the FcB2 (chloroquine-resistant) and NF-54 P. falciparum 
strains (sensitive to chloroquine, amodiaquine, quinine and artesunate but mefloquine-resistant). 
Table 1. In vitro biological activity of derivatives regarding Plasmodium falciparum FCB-2 
and NF-54 strains and on HepG2A (human hepatoma cell line). 
Compound IC50 μM ± SD RI * CC50 μM SI ** FCB-2 NF-54 
1 
  O
O
HO
A B
C D
E
 
>482.4 >482.4 1.0 1111.4 2.3 
2 
 
27.9 ± 5.5 35.4 ± 2.2 0.8 265.1 9.5 
3 
 
21.35 ± 0.2 32.96 ± 0.8 0.6 60.00 2.8 
4 
 
222.8 ± 12.3 248.0 ± 5.3 0.9 2145.7 9.6 
5 
 
38.2 ± 1.2 25.4 ± 1.6 1.5 193.0 5.0 
6 
 
>302.6 >302.6 1.0 >1145 3.8 
7 
 
 
70.4 ± 5.5 34.6 ± 3.3 2.0 216.7 3.1 
8 
 
 
>396 >396 1.0 >1981 7.8 
9 
 
 
56.1 ± 0.3 52.5 ± 7.7 1.1 >1166.6 30.7 
10 
 
 
56.7 ± 6.3 105.7 ± 7.7 0.5 100.6 1.8 
11 
 
 
>482.4 >482.4 1.0 >916.3 1.9 
12 
 
 
36.0 ± 2.3 29.2 ± 1.1 1.2 >487 6.6 
13 
 
 
63.2 ± 0.3 71.9 ± 0.3 0.9 >2411 38.2 
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Table 1. Cont. 
Compound IC50 μM ± SD RI * CC50 μM SI ** FCB-2 NF-54 
14 
 
 
10.1 ± 1.3 8.5 ± 2.3 1.2 153.4 15.2 
15 
 
O
O
O
I
 
2.9 ± 0.3 2.2 ± 0.4 1.3 90.2 31.1 
16 
 
 
>438.0 >438.0 1.0 >2,189.9 5.0 
17 
 
 
>409.3 183.8 2.2 >2,046.5 5.0 
18 
 
 
11.3 ± 1.6 9.8 ± 1.0 1.2 191.5 16.9 
19 
 
 
438.2 ± 12.0 369.6 ± 8.3 1.2 >2,521.4 6.5 
20 
 
>379.7 >379.7 1.0 >1,898.6 5.0 
21 
 
92.2 ± 12.3 70.8 ± 0.8 1.3 424.3 4.6 
22 
 
94.2 ± 5.3 62.1 ± 8.9 1.5 82.4 0.9 
23 
 
17.3 ± 1.4 0.6 ± 0.9 28.8 280.8 16.2 
24 
 
 
95.0 ± 7.3 100.9 ± 9.9 0.9 306.5 3.2 
25 
 
122.6 ± 12.8 95.9± 8.3 1.3 45.2 0.4 
CQ 
 
0.157 ± 0.01 0.02 ± 0.005 7.9 97.2 486.0 
AF-B 
 
   39.6  
* RI (resistance index) = IC50 FCB-2 (resistant strain)/IC50 NF-54 (sensitive strain); ** SI (selectivity index) 
= CC50 HepG2/IC50 parasite FCB-2; CQ: chloroquine (control of antiplasmodial assays); AF-B: amphotericin 
B (positive control of cytotoxicity assays). 
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Table 1 shows IC50, CC50 (50% cytotoxic dose in HepG2-A16 cells), selectivity index (SI = IC50/CC50) 
and resistance index values (RI = IC50 FCB-2/IC50 NF-54) for all compounds. Chloroquine had IC50  
157.9 nM in the FCB-2 strain and IC50 20 nM in the NF-54 strain. Diosgenin (1) lacked antiplasmodial 
activity since its IC50 was >482.4 µM against P. falciparum; however, diosgenone (2) was active, 
having IC50 27.9 µM in the FcB-2 strain and 35.4 µM IC50 in the NF-54 strain. 
Compounds 7, 9, 10 and 13 had marginal activity compared to diosgenone and 12 had similar 
activity to diosgenone, though derivatives 8 and 11 were inactive against both P. falciparum strains. 
Compounds 14 and 15 had high antiplasmodial activity (IC50 10.1 µM and 2.9 µM, respectively), and 
high SI (15.2 and 31.1, respectively). Compounds 16, 17, 19 and 20 were neither active nor toxic. 
However, more active compound 15 was very unstable since solution color in NMR tube changed 
from clear to deep brown, so its effect on P. berghei was not evaluated (iodine being generated during 
decomposition may have been responsible for such activity). Regarding RI, it was found that 
derivatives 2, 3, 4, and 10 had values below zero, indicating better antiplasmodial activity in 
chloroquine-resistant parasites. 
The importance of anunsaturated system in the molecules’ A-rings (exhibiting antiplasmodial 
activity) was demonstrated when the 3-en-1-one system was modified in diosgenone by hydrogenation 
or reduction (derivatives 7–13, but not 12). Such a system is present in progesterone 5, a compound 
exhibiting antiplasmodial action (IC50 38.2 µM), but lacking a spiroketal system; however, 17-OH 
progesterone 6 was an inactive compound. Compound 18 (having two carbonyl groups) was more 
active than diosgenone, indicating this system’s importance regarding antiplasmodial activity. 
SN-1 derivatives (3), 21–24 had a lower antiplasmodial effect than that of the natural compound 
(IC50 21.4 µM) but, surprisingly, diacetate 23 (IC50 17.3 µM) was more active in the FCB-2 strain 
(16.2 SI), as well as being less toxic. 
The Plasmodium berghei-infected mice model was used as a biological model for in vivo 
antimalarial tests; more active, stable, less cytotoxic compounds 14 and 18 were selected to establish 
in vivo effects. Antimalarial activity was expressed as the percentage of parasite multiplication 
inhibition. This assay found that all mice, except one, had an average 0.4% infected erythrocytes 24 h 
post-infection, at which time treatment was started with 100 mg/kg weight of the derivative or 5 mg/kg 
weight of CQ.  
Regarding mortality, all mice were alive until termination of the experiment (day 5) when they were 
then anesthetized and sacrificed. CQ-treated mice had 100.0% reduction of parasitemia on the second 
day of treatment; by contrast, mice treated with diosgenone (2) showed no decrease in the amount of 
parasites, reaching 50.0% parasitaemias on the fifth day post treatment. Such parasitemia was higher 
than that found in treated mice or untreated controls with the vehicle, reaching rates of 36.0% 
parasitized erythrocytes. Treating mice with derivatives 14 and 18 caused a therapeutic effect, leading 
to 36.7% and 35.0% reduction in parasitemia, respectively (Figure 2). Their low solubility in water and 
organic solvents must be considered (given that this concentration was relatively high), since there would 
have been reduced gastrointestinal absorption which could have affected an optimal therapeutic dose.  
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Figure 2. Percentage parasitemia inhibition in P. berghei-infected mice following 
treatment with derivatives 14 and 18. 
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It would also be interesting to evaluate these drugs’ therapeutic effect using a chronic model of 
malaria (such as Plasmodium chabaudi). A striking finding emerged on the third day of treatment with 
both derivatives during the above experiments; many P. berghei sexual forms became reduced, along 
with asexual parasitaemia on the fourth day of treatment. It may be thought that S. nudum steroid 
derivatives act similarly to progesterone (unsaturated system) in inducing differentiation into 
gametocytes of asexual parasites. Lingnau et al. [19] treated P. falciparum cultures with different 
concentrations of insulin, progesterone, 17--estradiol and testosterone, finding that insulin asexual  
in vitro density increased compared to controls. By contrast, parasitemia did not increase when adding 
steroidal hormones progesterone, 17--estradiol and testosterone asexual, but gametocyte development 
was much more pronounced when using these steroids in the treatment, mainly progesterone. 
2.3. Molecular Modeling 
3D-QSAR analysis followed the methodology described in Section 4.3 of this manuscript. The best 
model obtained after PLS analysis was a mixture of 70% electrostatic field and 30% steric field. Cross-
validated correlation coefficient q2 was 0.63, with 0.447 log units standard error of prediction at two 
components. This q2 value (greater than 0.5) indicated that a good predictive model had been obtained, 
in accordance with usual practice in the 3D-QSAR field. Compounds 4, 11, 21, 22 and 25 behaved as 
statistical outliers; this was probably due to the conformational variability associated with the D-ring 
substituents’ flexible chains introducing additional noise to the model. These compounds also had low 
to moderate bio-activity so their contribution to the model would not have been expected to have been 
very significant. 
The QSAR model was better depicted as 3D isosurfaces having standard deviation (stdev) 
multiplication values regarding the QSAR coefficient (coeff) at each point. This field gave information 
concerning the model’s salient features, specified by QSAR coefficients’ magnitude, scaled by 
associated variability at each grid point, specified by standard deviation [12]. 
Diosgenone (2)
Derivative 18
Derivative 14
CQ
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Figure 3 presents a stdev*coeff field contoured on compound 15; electrostatic and steric 
contributions are conveniently separated. Increased negative charge can be observed around steroidal 
skeleton A-, B- and D-rings (red mesh in Figure 3), associated with improved bio-activity, whereas 
increased positive charge around the D-ring decreased bio-activity. 
Figure 3. Electrostatic and steric contours mapped onto compound 15. 
 
 
A: Electrostatic field; B: Steric field. Electrostatic field - red and blue mesh surfaces; Steric field - yellow and 
green mesh surfaces; Two orientations are shown in the upper and lower parts of the Figure. 
Regarding steric contribution, increased steric volume beyond the D-ring (green mesh) correlated 
with positive contribution to bioactivity, whereas the yellow mesh around the A-ring meant negative 
steric field contribution to bioactivity. 
The fitting statistics for this model had a 0.958 correlation coefficient (estimated 0.1510 g units 
standard error). A comparison of the actual plot to the predicted one, showed the good correlation 
obtained. However, it should be mentioned that the standard error for the prediction given above only 
came from the statistical information provided by the model. 
It could be assumed from such observations that the steroidal skeleton provided a rigid framework 
having the right shape to accommodate specific electrostatic interactions with charged residues at the 
receptor’s active site, leaving room for an additional increase in steric volume beyond the D-ring. 
3. Experimental 
3.1. Chemistry 
3.1.1. General Procedures 
S. nudum steroid isolation and purification have already been described [5,6]; this involved 
reactions in an anhydrous nitrogen atmosphere using freshly-distilled, dry solvents prepared by 
standard methods. 4-Pregnene-3,20-dione, progesterone (5) and 17-hydroxy-4-pregnene-3,20-dione (6) 
were purchased from Sigma (St. Louis, MO, USA). Silica gel 60 (E. Merck, 70–230 mesh) was used 
for column chromatography purification. Thin-layer chromatography and nuclear magnetic resonance 
A B
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(NMR) were used for checking all new compounds’ purity. All reactions were monitored by TLC 
analysis on pre-coated silica gel F254 plates (E. Merck). Melting points (uncorrected) were determined 
by electrothermal equipment (Electrothermal 3100) and a spectrometer was used for infrared (IR) 
analysis (Thermo Nicolet Avatar 330 FT-IR, DTGS KBr). A spectrometer (Bruker AC 300) recorded 
1H-, 13C- and 1H-decoupled spectra at 300 and 75 MHz. Chemical shifts () obtained in CDCl3 were 
reported per million (ppm) relative to the residual solvent proton (7.26 ppm) and carbon signals (77.2). 
Only assignable signals were listed. Low resolution mass spectra were obtained in positive mode 
electrospray ionization mass spectra (ESI-MS) coupled to high-performance liquid chromatography 
(HPLC) apparatus (Agilent series 1200 model VL, Palo Alto, CA, USA) equipped with an atmospheric 
pressure ionization source. 
3.1.2. Chemical Transformations  
The pertinent literature contains very few publications regarding diosgenone synthesis; these have 
dealt with the Oppenauer reaction with aluminum alkoxides [20], or ruthenium complexes [21]. 
However, yields have been poor or absent. Enzymatic transformations have also been attempted with 
structurally-similar molecules [22,23]. Obtaining diosgenone via Swern oxidation with subsequent 
double bond isomerization with oxalic acid in refluxing ethanol is reported here (84% overall yield). 
(25R)-4-Spirosten-3-one, diosgenone (2). A mixture of oxalyl chloride (1.08 mmol, 136 mg, 2 eq.) in 
dichloromethane (DCM, 5 mL) was treated with dimethyl sulfoxide (DMSO, 0.23 mL, 1.08 mmol, 84 mg, 
2 eq.) in DCM (5 mL) and stirred at −60 °C for 5 min. (25R)-5-spirosten-3β-ol (3β-hydroxy-5-
spirostene, diosgenin 1, 300 mg, 0.72 mmol, 1 eq.) in DCM (20 mL) was then added to the reaction 
mixture. Temperature was allowed to reach −10 °C after 20 min and then 0.65 mL N,N-diisopropyl 
ethylamine (3.73 mmol, 482 mg, 5.2 eq.) were added; stirring was continuous for 1 h to reach room 
temperature (RT) and HCl (20 mL, 5%) was added. The combined organic layer was washed with an 
aqueous solution (aq) of NaHCO3 (30 mL), dried (Na2SO4) and evaporated under reduced pressure. 
The residue was dissolved in an oxalic acid solution (1.4 g, 15.5 mmol, 21.5 eq.) in ethanol (20 mL) 
and heated to reflux for 5 h, extracted with DCM (3 × 15 mL), dried (Na2SO4) and evaporated under 
reduced pressure. The residue was purified by chromatography on silica and eluted with 4:1:1 
hexane/DCM/Ethyl acetate (EtOAc), yielding diosgenone (2), as a white solid (255 mg, 84%), Rf = 0.6 
(hexane/EtOAc 4:1). Melting point (m.p.): 188–190 °C. IR (KBr): 2950, 1680, 1470. 1H- NMR 
(CDCl3) δ: 5.6 (s, 1H, H-4), 4.3 (dd, J1 = 14.0 Hz, J2 = 7.0 Hz, 1H, H-16), 3.4 (dd, J1 = 11.0 Hz,  
J2 = 3.0 Hz, 1H, H-26), 2.5 (dt, J1 = 17.0 Hz, J2 = 7.0 Hz 1H, H-2), 2.4 (dt, J1 = 15.0 Hz, J2 = 12.0 Hz, 
1H, H-2), 1.12 (s, 3H, H-19), 0.88 (d, J = 7.0 Hz, 3H, H-21), 0.76 (s, 3H, H-18), 0.72 (d, J = 6.3, 3H, 
H-27); 13C-NMR (CDCl3) δ: 199.3 (C-3), 171.0 (C-5), 123.7 (C-4), 109.1 (C-22), 80.4 (C-16), 66.7  
(C-26), 61.9 (C-17), 55.5 (C-14), 53.6 (C-9), 41.5 (C-20), 40.2 (C-13), 39.5 (C-12), 38.5 (C-10), 35.5 
(C-1), 35.0 (C-8), 33.8 (C-2), 32.6 (C-6), 32.0 (C-7), 31.6 (C-15), 31.2 (C-23), 30.1 (C-25), 28.6 (C-24), 
20.7 (C-11), 17.2 (C-19), 17.0 (C-27). 16.2 (C-18), 14.4 (C-21). MS (m/z) (%): 413.0 (M+, 100). 
(25R)-3-Methyl-spirostan-2,4-diene (7). Diosgenone (2, 25 mg, 0.6 mmol, 1 eq.) in diethyl ether (5 mL) 
was treated with methyl magnesium bromide solution (0.44 mL, 0.62 mmol, 1.1 eq., 1.4 M 
toluene/THF 3:1) and stirred at −15 °C (one hour) followed by 2 h at RT. The reaction mixture was 
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slowly treated with 5% aq NH4Cl (20 mL) and extracted with three  20 mL portions of DCM. The 
combined organic extract was washed with water (20 mL) and brine (20 mL). The dried (Na2SO4) 
organic phase was concentrated under reduced pressure. The residue was purified by chromatography 
on a silica gel column (DCM/hexane 8:1) yielding compound 7 (14 mg, 54%): Rf = 0.4 (DCM). M.p.: 
172–174 °C. IR (KBr): 2928. 1H-NMR (CDCl3) δ: 5.8 (s, 1H, H-4), 5.4 (dd, J = 5.0 Hz, 1H, H-2), 4.4 
(dt, J1 = 7.9 Hz, J2 = 1.8 Hz, 1H, H-16), 3.5 (d, J = 10.7 Hz, 2H, H-26), 1.7 (s, 3H, Me), 1.0 (s, 3H, H-19), 
0.9 (d, J = 7.1 Hz, 3H, H-21), 0.8 (s, 3H, H-18), 0.72 (d, J = 6.3, 3H, H-27);13C-NMR (CDCl3) δ: 
142.0 (C-5), 133.4 (C-3), 130.4 (C-2), 124.8 (C-4), 120.9 (C-6), 109.7 (C-22), 81.3 (C-16), 67.3 (C-26), 
62.5 (C-17), 57.1 (C-14), 48.7 (C-9), 40.8 (C-20), 40.3 (C-13), 32.1 (C-6), 32.0 (C-15), 31.9 (C-23), 
31.8 (C-25), 28.9 (C-24), 28.3 (C-11), 24.3 (Me), 21.3 (C-18), 19.4 (C-27), 16.8 (C-18), 14.9 (C-21). 
MS (m/z) (%): 411.2 (M+, 10).  
(25R)-3-Benzyl-spirostan-4-en-3-ol (8). Diosgenone (2, 50 mg, 0.12 mmol, 1 eq.) in diethyl ether (5 mL) 
was treated with benzylmagnesium bromide solution (0.14 mL, 0.14 mmol, 1.1 eq., 1.0 M THF) and 
treated as above. The residue was purified by chromatography on a silica gel column (DCM/hexane 
8:1) yielding compound 8 as a white solid (56 mg, 92%): Rf = 0.4 (hexane/EtOAc 8:1). M.p.: 203–205 °C. 
IR (KBr): 2930, 2880, 1600–1700. 1H-NMR (CDCl3) δ: 7.40–7.09 (m, 5H, H-Ar), 5.1 (s, 1H, H-4), 4.4 
(dt, J1 = 7.9, J2 1.7 Hz, 1H, H-16), 3.4 (d, J = 10.7 Hz, 2H, H-26), 2.8 (d, J = 14.7 Hz, 2H, Ar-CH2), 
1.1 (s, 3H, H-19), 1.0 (d, 7.1 Hz, 3H, H-21), 0.8 (s, 3H, H-18), 0.8 (d, J = 6.2 Hz, 3H, H-27); 13C-NMR 
(CDCl3) δ: 146.8 (C-1'), 137.7 (C-5), 131.1 (C-4'), 129.3 (C-3', C-5'), 126.8 (C-2', C-4'), 126 (C-4), 
109.7 (C-22), 81.2 (C-16), 71.7 (C-3), 67.3 (C-26), 62.5 (C-17), 56.4 (C-14), 54.8 (C-9), 47.2 (C-20), 
40.3(C-13), 32.2 (C-6), 32.1 (C-15), 31.2 (C-22), 30.1 (C-25), 29.2 (C-26), 29.1 (C-10), 28.6 (C-23), 
28.4 (C-24), 21.4 (C-19), 20.6 (C-11), 17.5 (C-27), 16.8 (C-18), 14.9 (C-21). MS (m/z) (%): 506.2  
(M+ +1, 5), 487.2 (86). 
(25R)-3-p-Toluenehydrazine-spirostan-4-ene (9). A mixture of diosgenone (2, 102 mg, 0.25 mmol, 1 eq.) 
and pTsNHNH2 (118 mg, 0.65 mmol, 2.6 eq.) in ethanol (5 mL) was heated to reflux for 5 h. The 
solvent was evaporated under vacuum and the residue was purified by chromatographic column on 
silica gel (hexane/EtOAc 5:1) yielding compound 9 as a white solid (122 mg, 84%): Rf = 0.45 
(hexane/EtOAc 5:1). M.p.: 148–150 °C. IR (KBr): 3508, 2930. 1H-NMR (CDCl3) δ: 7.9 (d, J = 8.1 Hz, 
2H, H-Ar), 7.3 (d, J = 8.1 Hz, 2H, H-Ar), 5.8 (s, 1H, H-4), 4.4 (dt, J1 = 7.9 Hz, J2 = 1.8 Hz, 1H, H-16), 
3.4 (d, J = 10.7 Hz, 2H, H-26), 2.4 (s, 3H, Ar-CH3), 1.0 (s, 3H, H-19), 0.9 (d, J = 7.2 Hz, 3H, H-21), 
0.76 (s, 3H, H-18), 0.7 (d, J = 6.3 Hz, 3H, H-27); 13C-NMR (CDCl3) δ: 145.0 (C-5), 142.6 (C-3), 139.8 
(C-1'), 136.4 (C-4'), 129.9 (C-3', C-5'), 129.1 (C-4), 128.5 (C-3', C-5'), 120.8 (C-2', C-6'), 109.7 (C-22), 
81,6 (C-16), 62.5 (C-26), 56.2 (C-17), 53.9 (C-14), 42,3 (C-20), 35.7 (C-8), 29.2 (C-23), 29.0 (C-10), 
28.8 (C-1), 28.7 (C-2), 28.5 (C-15), 28.4 (C-6), 28.2 (C-25), 28.1 (C-24), 20.8 (C-11), 20.6 (C-Me) 
17.5 (C-19), 16.7 (C-27), 14.9 (C-21), 14.5 (C-18), 14.1 (C-21). MS (m/z) (%): 581.3 (M+, 5); 539.1 (36). 
(25R)-4,5-Epoxy-spirostan-3-one (10). A mixture of diosgenone (2, 30 mg, 0.073 mmol, 1 eq.) and 
hydrogen peroxide (0.5 mL, 30%, 4.9 mmol, 67 eq.) in DCM/acetone 1:1 (20 mL) was treated with 
NaOH (1 mL, 2%) and stirred at RT for 48 h; then water was added to the reaction mixture and 
extracted with ethyl acetate (2 × 15 mL). The combined organic layer was washed with an aq NaHCO3 
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solution (30 mL), dried (Na2SO4) and evaporated under reduced pressure. The residue was purified by 
chromatography on a silica gel column (hexane/EtOAc 10:1) yielding compound 10 as a white solid 
corresponding to the mixture of epoxides α (70%) y β (30%) (21 mg, 65%): Rf = 0.6 (hexane/EtOAc 
9:1). M.p.: 184–186 °C. IR (KBr): 2899, 1715. 1H-NMR (CDCl3) δ: 4.4 (dt, J1 = 7.9 Hz, J2 = 1.8 Hz, 
1H, H-16), 3.3 (d, J = 10.7 Hz, 2H, H-26), 3.0 (s, 1H, H-4), 2.9 (s, 1H, H-4), 1.2 (s, 3H, H-19), 1.0 
(d, J = 7.1 Hz, 3H, H-21), 0.8 (s, 3H, H-18), 0.8 (d, J = 6.2 Hz, 3H, H-27); 13C-NMR (CDCl3) δ: 207.2 
(C-3), 109.7 (C-22), 82.0 (C-16), 70.5 (C-5), 67.3 (C-26), 63.3 (C-4), 63.2 (C-17), 60.4 (C-17), 55.8 
(C-14), 48.1 (C-9), 40.6 (C-12), 35.2 (C-20), 35.0 (C-17), 34.5 (C-8), 34.5 (C-10), 34.0 (C-2), 32.4 (C-1), 
31.5 (C-15), 30.7 (C-6), 28.9 (C-23), 28.5 (C-7), 27.4 (C-24), 21.1 (C-11), 16.9 (C-27), 16.2 (C-19), 
15.1 (C-21), 14.6 (C-18). MS (m/z) (%): 429.2 (M+, 82), 427.2 (12). 
(25R)-Spirostan-3-one (11). A mixture of diosgenone (2, 40.8 mg, 0.1 mmol, 1 eq.) and palladium on 
carbon (Pd/C) 10% (2.0 mg, 10% mol, 0.01 mmol) in EtOAc (5 mL) was treated with hydrogen and 
stirred at RT overnight. The reaction mixture was filtered through a pad of celite and the solvent was 
evaporated under reduced pressure. The residue was purified by chromatography on a silica gel 
column (hexane/EtOAc 10:1) yielding compound 11 as a white solid (35 mg, 85%): Rf = 0.4 
(hexane/AcOEt 10:1). M.p.: 153–155 °C. IR (KBr): 2929, 1712. 1H-NMR (CDCl3) δ: 4.4 (dt, J1 = 7.9 Hz, 
J2 = 1.8 Hz, 1H, H-16), 3.4 (d, J = 10.7 Hz, 2H, H-26), 2.6 (d, J = 15.1 Hz, 2H, H-4), 1.1 (dt, J1 = 7.6 Hz, 
J2 3.6 Hz, 2H, H-6), 1.0 (s 3H, H-18), 0.9 (d, J = 7.0 Hz, 3H, H-21), 0.7 (d, J = 6.3 Hz, 3H, H-27);  
13C-NMR (CDCl3) δ: 210.0 (C-3), 109.7 (C-22), 81.2 (C-16), 67.3 (C-26), 62.6 (C-17), 56.7 (C-14), 
44.6 (C-4), 41.1 (C-20), 40.3 (C-13), 38.9 (C-12), 38.2 (C-1), 38.1 (C-2), 35.8 (C-10), 35.0 (C-8), 31.6  
(C-15), 30.7 (C-23), 28.6 (C-24, C-6), 20.8 (C-11), 19.9 (C-27), 17.5 (C-21), 16.8 (C-18), 14.9 (C-19). 
MS (m/z) (%): 415.2 (M+, 86), 397.1 (6). 
(25R)-1,4-Spirostadien-3-one (12). A mixture of diosgenone (2, 50.0 mg, 0.1 mmol, 1 eq.), benzoic 
acid (14.8 mg, 0.12 mmol, 1.1 eq.) and 2,3-Dichloro-5,6-dicyano-p-benzoquinone (DDQ, 40.9 mg, 
0.18 mmol, 1.8 eq.) was dissolved in 10.0 mL toluene and then heated to reflux for 12 h. The reaction 
mixture was filtered through celite and the solvent was evaporated under reduced pressure. The residue 
was purified by chromatography on a silica gel column (hexane/DCM/EtOAc 4:1:1) yielding 
compound 12 as a white solid (30 mg, 60%): Rf = 0.3 (hexane/AcOEt 10:1). M.p.: 181–183 °C. IR 
(KBr): 2933, 2854, 1664, 1458. 1H-NMR (CDCl3) δ: 7.1 (d, J = 10.0, 1H, H-1), 6.3 (d, J = 10.0, 1H, 
H-2), 6.1 (s, 1H, H-4), 4.4 (dt, J1 = 7.9 Hz, J2 = 1.8 Hz, 1H, H-16), 3.6(d, J = 10.7 Hz, 2H, H-26), 2.6 
(dt, J1 = 14.4, Hz J2 = 12.0 Hz, 2H, H-6), 1.3 (s, 3H, H-19), 0.9 (d, J = 7.1 Hz, 3H, H-21), 0.8 (d,  
J = 6.3 Hz, 3H, H-27), 0.7 (s, 3H, H-18); 13C-NMR (CDCl3) δ: 187.1 (C-3), 170.2 (C-5), 156.7 (C-1), 
127.8 (C-2), 124.2 (C-4), 109.8 (C-22), 80.9 (C-16), 67.0 (C-26), 62.4 (C-17), 55.2 (C-14), 52.8 (C-9), 
44.2 (C-10), 42.1 (C-20), 41.1 (C-13), 39.9 (C-12), 35.6 (C-8), 34.2 (C-7), 33.5 (C-6), 33.1 (C-15), 
32.3 (C-23), 31.1 (C-25), 30.7 (C-24), 23.2 (C-11), 19.1 (C-19), 17.6 (C-27), 16.9 (C-18), 14.9 (C-21). 
MS (m/z) (%): 411.1 (M+, 100). 
(25R)-4-Spirosten-3-ol (13). Diosgenone (2, 24 mg, 0.06 mmol, 1 eq.) in methanol (5 mL) was treated 
with NaBH4, (80 mg, 0.2 mmol, 3.3 eq.) and stirred at RT for 2 h overnight; water was then added to 
the reaction mixture and extracted with DCM (2 × 15 mL). The combined organic layer was washed 
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with an aq NaHCO3 solution (30 mL), dried (Na2SO4) and evaporated under reduced pressure. The 
residue was purified by chromatography on a silica gel column (hexane/EtOAc 5:1) yielding 
compound 13 as a white solid (21 mg, 65%): Rf = 0.4 (hexane/AcOEt 5:1). M.p.: 116–118 °C. IR 
(KBr): 3264, 2930, 2846, 1448. 1H-NMR (CDCl3) δ: 5.3 (d, J = 6.5 Hz, 1H, H-4), 4.4 (dt, J1 = 15.0,  
J2 = 7.5 Hz, 1H, H-16), 4.1 (dd, J1 = 18.0 Hz, J2 = 6.5 Hz, 1H, H-3), 3.5–3.3 (d, J = 10.7 Hz, 2H,  
H-26), 2.3 (dd, J1 = 14.0 Hz, J2 = 12.0 Hz, 1H, H-6), 1.0 (s, 3H, H-18), 0.9 (d, J = 6.9 Hz, 3H, H-21), 
0.8 (s, 3H, H-19), 0.7 (d, J = 6.2 Hz, 3H, H-27); 13C-NMR (CDCl3) δ: 147.8 (C-5), 123.9 (C-4), 109.7 
(C-22), 81.2 (C-16), 68.3 (C-3), 67.2 (C-26), 62.5 (C-17), 56.4 (C-14), 54.8 (C-9), 40.8 (C-20), 39.8 
(C-13), 39.6 (C-12), 38.4 (C-10), 37.7 (C-1), 35.9 (C-8), 30.7 (C-25), 29.9 (C-2), 29.2 (C-24), 21.2 (C-11), 
17.2 (C-19), 16.8 (C-27), 16.2 (C-18), 14.9 (C-21). MS (m/z) (%): 415.2 (M+, 80), 413.2 (21). 
(25R)-4,5-Epoxy-spirostan-16α-hydroxy-3-one (14). A mixture of diosgenone (2, 200 mg, 0.48 mmol, 
1 eq.) and NaHCO3 (1.89 g, 22.5 mmol, 47 eq.) in CHCl3-acetone-1.0 mM Na2EDTA (1:1:1, 37.5 mL, 
4.65 g, 12.5 mmol, 26 eq.) was treated with oxone (6 g, 9.8 mmol, 20.4 eq.) in EDTA-Na2 (1 Mm) and 
stirred at RT for 48 h. The reaction mixture was extracted with DCM (2 × 15 mL) and the combined 
organic layer was washed with an aq NaHCO3 solution (30 mL), dried (Na2SO4) and evaporated under 
reduced pressure. The residue was purified by chromatography on a silica gel column (hexane/DCM 
/EtOAc 3:1:1) yielding compound 14 as a white solid corresponding to the mixture of epoxides α 
(70%) y β (30%) (170 mg, 80%): Rf = 0.55 (hexane/AcOEt 3:1). M.p.: 145–147 °C. IR (KBr): 3450, 
2940, 1710. 1H-NMR (CDCl3) δ: 3.6 (d, J1 = 10.7 Hz, J2 = 8.2 Hz, 2H, H-26), 3.0 (s, 1H, H-4α), 2.97 
(s, 1H, H-4β), 1.8 (dd, J1 = 17.6 Hz, J2 = 2.4 Hz, 2H, H-2), 1.5 (d, J = 10.7 Hz, 2H, H-15), 1.0 (d,  
J = 7.1 Hz, 3H, H-21), 1.0 (s, 3H, H-18), 0.8 (s, 3H, H-19), 0.8 (d, J = 6.2 Hz, 3H, H-27). 13C-NMR 
(CDCl3) δ: 207.7 (C-3), 116.5 (C-22), 111.6 (C-16), 70.8 (C-5), 70.7 (C-3), 68.7 (C-26), 63.3 (C-4), 
55.2 (C-17), 51.0 (C-15), 47.0 (C-9), 42.9 (C-15), 40.3 (C-12), 39.4 (C-20), 37.6 (C-8), 33.2 (C-1), 
32.7 (C-6), 31.5 (C-23), 30.3 (C-25), 29.8 (C-24), 29.7 (C-1), 29.2 (C-7), 27.2 (C-2), 21.8 (C-11), 20.0 
(C-11), 18.0 (C-27), 16.0 (C-19), 15.5 (C-18), 15.0 (C-21). MS (m/z) (%): 445.0 (M+, 3), 427.0 (96). 
(25R)-26-Iodine-cholest-4-en-3,16,22-trione (15). A mixture of sodium iodide (NaI, 3 g, 20 mmol, 20 eq.), 
TMSCl (0.63 mL, 5 mmol, 5 eq.) and molecular sieve (5 g) in CH3CN (24 mL) was stirred at RT for 2 h. 
Compound 9 (446 mg, 1 mmol, 1 eq.) in DCM (15 mL) was added for 20 min. The reaction mixture 
was extracted with DCM (2 × 15 mL) and the combined organic layer was washed with an aq NaHCO3 
solution (30 mL), dried (Na2SO4) and evaporated under reduced pressure. The residue was purified by 
chromatography on a silica gel column (hexane/DCM/EtOAc 2:1:1) yielding compound 15 as a white 
solid (404 mg, 75%): Rf = 0.4 (hexane/EtOAc 2:1). M.p.: 148–150 °C. IR (KBr): 2942, 1733, 1717. 
1H-NMR (CDCl3) δ: 5.7 (s, 1H, H-4), 3.3 (d, J = 4.9 Hz, 2H, H-26), 2.6 (d, J = 8.6 Hz, 1H, H-17), 1.6 
(d, J = 16.4 Hz, 2H, H-23), 1.2 (d, J = 12.0 Hz, 3H, H-21), 1.1 (d, J = 6.2 Hz, 3H, H-27), 1.0 (s, 3H, 
H-18), 0.8 (s, 3H, H-19); 13C-NMR (CDCl3) δ: 218.2 (C-16), 213.7 (C-22), 199.9 (C-3), 170.8 (C-5), 
124.9 (C-4), 66.9 (C-17), 53.9 (C-9), 51.2 (C-14), 44.0 (C-), 42.5 (C-13), 40.2 (C-20), 39.3 (C-12), 
39.2 (C-15), 39.0 (C-10), 36.2 (C-23), 36.1 (C-8), 34.6 (C-1), 34.5 (C-24), 33.2 (C-2), 32.7 (C-6), 30.6 
(C-7), 21.2 (C-25), 20.9 (C-27), 18.6 (C-11), 18.1 (C-26), 17.6 (C-19), 16.1 (C-21), 13.8 (C-18). MS 
(m/z) (%): 539.1 (M+, 96), 500.1 (5). 
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(25R)-3-Acetoxy-spirostan-5-ene (16). A mixture of diosgenine (1, 500 mg, 1.2 mmol, 1 eq.), acetic 
anhydride (1 mL, 1.05 mmol, 8.8 eq.) and ZnCl2 (0.5 g, 3.6 mmol, 3 eq.) was stirred at RT for 3 h. An 
Na2CO3 solution was added to the reaction mixture and extracted with EtOAc (2 × 15 mL), dried 
(Na2SO4) and evaporated under reduced pressure. The residue was purified by chromatography on a 
silica gel column (hexane/EtOAc/DCM 5:1:1) yielding compound 16 as a white solid (452 mg, 82%) 
Rf = 0.5 (hexane/EtOAc 3:1). M.p.: 182–184 °C. 1H-NMR (CDCl3) δ: 5.4 (d, 1H, J = 4.7 Hz, H-6), 4.6 
(m, 1H, H-3), 4.4 (dt, 1H, J1 = 15 Hz, J2 = 7 Hz, H-16), 3.5(d, J = 10.7 Hz, 2H, H-26), 2.1 (s, 3H,  
3-OCOCH3), 1.6 (s 3H, H-18), 1.0 (s 3H, H-19), 0.9 (d, 3H, J = 7.1 Hz, H-21), 0.8 (d, 3H, J = 6.3 Hz, 
H-27); 13C-NMR (CDCl3) δ: 170.5 (3-OCOCH3), 139.6 (C-5), 122.3 (C-6), 109.2 (C-22), 80.8 (C-16), 
73.8 (C-3), 66.8 (C-26), 62.0 (C-17), 56.4 (C-14), 49.9 (C-9), 41.6 (C-20), 40.2 (C-13), 39.7 (C-4), 
38.0 (C-12), 36.9 (C-1), 36.7 (C-10), 32.0 (C-7), 31.8 (C-15), 31.4 (C-8), 31.3 (C-23), 30.3 (C-25), 
28.8 (C-2), 27.7 (C-24), 21.4 (3-OCH3), 20.8 (C-11), 19.3 (C-19), 17.1 (C-27), 16.2 (C-18), 14.5 (C-21). 
(25R)-5,6-Epoxy-spirostan-3-ol (17). A mixture of diosgenine (1, 100 mg, 2.0 mmol, 1 eq.) and 
NaHCO3 (1.89 g, 22.5 mmol, 11 eq.) in CHCl3-acetone-1.0 mM Na2EDTA (1:1:1, 37.5 mL) was 
treated with oxone (6.0 g, 9.8 mmol) in Na2EDTA 1mM and stirred at RT for 16 h. The reaction 
mixture was extracted with DCM (2 × 15 mL). The combined organic layer was washed with an aq 
NaHCO3 solution (30 mL), dried (Na2SO4) and evaporated under reduced pressure. The residue was 
purified by chromatography on a silica gel column (hexane/DCM/EtOAc 1:1:1) yielding compound 17 
as a white solid corresponding to the mixture of epoxides α (70%) y β (30%) (85.1 mg, 70.1%): Rf = 0.4 
(hexane/EtOAc 2:3). M.p.: 97–99 °C. 1H-NMR (CDCl3) δ: 4.38 (dd, 1 H, J = 7.4 Hz, H-16), 3.9 (m, 
1H, H-3), 3.5 (dd, 1H, J = 11, 3 Hz, H-26), 3.36 (dd, 1H, J = 11 Hz, H-26), 3.10 (d, 1H, J = 4Hz,  
H-6β), 2.92 (d, 1H, J = 4 Hz, H-6α), 1.09 (s, 3H, H-19), 0.97 (d, 3H, J = 7 Hz, H-21), 0.80 (d,3H, J = 6 Hz, 
H-27), 0.74 (s, 3H, H-18); 13C-NMR (CDCl3) δ: 110.0 (C-22), 81.3 (C-16), 69.3 (C-3), 67.5 (C-26), 
66.4 (C-5), 62.6 (C-17), 59.8 (C-6), 55.7 (C-14), 43.3 (C-4), 42.3 (C-12), 41.0 (C-13), 40.5 (C-20), 
35.7 (C-10), 32.4 (C-1), 31.8 (C-15), 31.7 (C-7), 31.0 (C-23), 30.1 (C-9), 30.0 (C-26), 29.7 (C-2), 29.5 
(C-24), 22.5 (C-11), 17.0 (C-27), 16.9 (C-19), 16.7 (C-21), 15.2 (C-18). 
(25R)-4-Spirosten-3,6-dione (18). A mixture of diosgenine (1, 50 mg, 0.12 mmol, 1 eq.) and 
pyridinium chlorochromate (PCC, 100 mg, 0.46 mmol, 3.8 eq.) in DCM (30 mL) was stirred at RT for 
5 h. The reaction mixture was extracted with DCM (2 × 15 mL). The combined organic layer was 
washed with an aq NaHCO3 solution (30 mL), dried (Na2SO4) and evaporated under reduced pressure. 
The residue was purified by chromatography on a silica gel column (hexane/DCM/EtOAc 2:1:1) 
yielding compound 18 as a yellow solid (28 mg, 55%): Rf = 0.3 (hexane/AcOEt/DCM 7:1:1). M.p.: 
200–202 °C. IR (KBr): 2951, 2925, 2850, 1700. 1H-NMR (CDCl3) δ: 6.2 (s, 1H, H-4), 4.42 (dd,  
J1 = 7.6 Hz, J2 = 13.8 Hz, 1H, H-16), 3.5(d, J = 10.7 Hz, 2H, H-26), 2.8 (d, J = 14.7 Hz, 2H, H-7), 1.2 
(s, 3H, H-19), 1.0 (d, J = 7.1 Hz, 3H, H-21), 0.8 (d, J = 6.2 Hz, 3H, H-27), 0.7 (s, 3H, H-18);  
13C-NMR (CDCl3) δ: 202.1 (C-7), 199.6 (C-3), 160.8 (C-5), 125.9 (C-4), 109.6 (C-22), 80.5 (C-16), 
67.2 (C-26), 62.1 (C-17), 56.5 (C-14), 51.1 (C-9), 47.0 (C-7), 41.9 (C-20), 40.7 (C-12), 39.9 (C-13), 
39.4 (C-10), 35.7 (C-1), 34.2 (C-2), 33.9 (C-8), 31.7 (C-15), 31.5 (C-23), 30.4 (C-25), 29.0 (C-24), 
20.9 (C-11), 17.8 (C-19), 17.3 (C-27), 16.5 (C-18), 14.7 (C-21). MS (m/z) (%): 427.0 (M+, 100). 
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(25R)-3,5-Spirostadiene (19). HCl (2.5 mL, 36.5%, 31.8 mmol, 635 eq.) was added to a solution of 
diosgenine (1, 20 mg, 0.05 mmol, 1 eq.), zinc powder (250 mg, 3.8 mmol, 76 eq.) in ethanol (5 mL) 
and stirred at RT for 2 h. NaOH (15 mL, 10%) was added to the reaction mixture and extracted with 
DCM (2 × 15 mL). The combined organic layer was washed with an aq NaHCO3 solution (30 mL), 
dried (Na2SO4) and evaporated under reduced pressure. The residue was purified by chromatography 
on a silica gel column (DCM/methanol (MeOH) 100:1) generating 19 as white solid (13 mg, 71%):  
Rf = 0.5 (DCM/MeOH 20:1). M.p.: 116–118 °C. 1H-NMR (CDCl3) δ 5.9: (d, J = 4.0 Hz, 1H, H-3), 5.8 
(d, J = 4.0 Hz, 1H, H-4), 5.3 (dd, J = 6.0, 1.3 Hz, 1H, H-6, 4.39 (dt, J1 = 7.6 Hz, J2 = 13.8 Hz, 1H,  
H-16), 3.4 (d, J = 10.7 Hz, 2H, H-26), 1.2 (s, 3H, H-19), 1.0 (d J = 7.1 Hz, 3H, H-21), 0.9  
(d, J = 6.2 Hz, 3H, H-27), 0.8 (s, 3H, H-18); 13C-NMR (CDCl3) δ: 141.9 (C-5), 129.3 (C-3), 125.4  
(C-4), 123.1 (C-6), 109.7 (C-22), 81.2 (C-16), 67.2 (C-26), 62.5 (C-17), 57.2 (C-14), 48.7 (C-9), 41.8 
(C-20), 40.3 (C-12), 35.3 (C-10), 34.6 (C-1), 34.0 (C-8), 33.7 (C-15), 33.4 (C-23), 32.0 (C-8), 30.6  
(C-25), 28.9 (C-24), 23.3 (C-2), 21.1 (C-11), 19.1 (C-19), 18.2 (C-27), 17.5 (C-18), 16.6 (C-21). 
(25R)-23-Acetyl-3,16-diacetoxy-22,23-pyran-cholesta-5,22-diene (20). ZnCl2 (1.0 g, 7.2 mmol, 6 eq.) 
was added to a solution of diosgenine (1, 500 mg, 1.2 mmol, 1 eq.) in acetic anhydride (5 mL, 0.5 mmol, 
0.4 eq.) and stirred at RT for 72 h. Water was added to the reaction mixture and extracted with EtOAc 
(3 × 15 mL). The combined organic layer was washed with an aq NaHCO3 solution (30 mL), dried 
(Na2SO4) and evaporated under reduced pressure. The residue was purified by chromatography on a 
silica gel column (hexane/EtOAc/DCM, 9:1:1) yielding compound 20 as a white solid (620 mg, 96%): 
Rf = 0.6 (hexane/EtOAc 4:1).1H-NMR (CDCl3) δ: 5.3 (d, J = 4.3Hz, 1H, H-6), 5.1 (dt, J1 = 5.9 Hz,  
J2 = 4.9 Hz, 1H, H-16), 4.6 (dt, J = 12.9, 8.1 Hz, 1H, H-3), 4.0 (dd, J1 = 10.7 Hz, J2 = 4.7 Hz, 2H,  
H-26), 2.9 (dd, J = 6.5 Hz, 1H, H-20,), 2.2 (s, 3H, 28-COCH3), 2.0 (s, 3H, 3-OCOCH3), 1.9 (s, 3H,  
16-OCOCH3), 1.2 (d, J = 7.0 Hz, 3H, H-21,), 1.0 (s, 3H, H-19), 0.9 (s, 3H, H-18,), 0,8 (d, J = 6.3, 3H, 
H-27); 13C-NMR (CDCl3) δ: 198.1 (C-27), 171.3 (C-22), 170.6 (16-OCOCH3), 170.4 (3-OCOCH3), 
139.7 (C-5), 122.2 (C-6), 106.9 (C-23), 75.1 (C-16), 73.8 (C-3), 71.5 (C-26), 55.9 (C-17), 54.2 (C-14), 
49.9 (C-9), 42.2 (C-13), 39.7 (C-12), 38.0 (C-4), 36.8 (C-1), 36.5 (C-10), 34.8 (C-15), 32.8 (C-20), 
31.6 (C-24), 31.5 (C-7), 31.3 (C-8), 29.7 (COCH3), 28.4 (C-28), 27.8 (C-2), 22.2 (C-11), 21.2 (C-25), 
21.3 (COCH3), 20.7 (C-19 C24), 19.3 (C-21), 19.2 (C-18).  
(25R)-16-Acetoxy-4-cholesten-3,22-dione-26-al (21). DMSO (0.2 mL, 2.8 mmol, 93 eq.) was added 
dropwise to a solution of (COCl)2 (0.1 mL, 2.3 mmol, 29 eq.) in DMC (5 mL) at −60 °C and the 
resulting solution was stirred for 15 min. A solution of SN-1 (14.2 mg, 0.03 mmol, 1 eq.) in DMC (3 mL) 
was added dropwise to this solution and stirred for 30 min. (iPr)2NEt (0.62 g, 4.8 mmol, 162 eq.) was 
added dropwise, and the solution was warmed at RT for 1 h. The solution was diluted with water (10 mL) 
and extracted with DCM (4 × 15 mL). The organic extracts were combined, washed with water (30 mL), 
brine (30 mL), dried over Na2SO4, and concentrated in vacuo to yield 21 as a white solid. (8.2 mg, 
58.1%): Rf = 0.6 (hexane/EtOAc 1:2). 1H-NMR (CDCl3) δ: 9.6 (s, 1H, CHO), 5.7 (s, 1H, H-4), 4.9 (dt, 
J = 10.7, 5.9 Hz, 1H, H-16), 2.6 (dd, J = 16.4, 86 Hz, 2H, H-23), 2.0 (s, 3H, 16-OCOCH3), 1.2 (s, 3H, 
H-19), 1.1 (d, J = 7.1 Hz, 3H, H-27), 1.0 (d, J = 7.1 Hz, 3H, H-21), 0.9 (s, 3H, H-18); 13C-NMR 
(CDCl3) δ: 212.2 (C-22), 204.4 (C-26), 199.4 (C-3), 170.7 (16-OCOCH3), 170.6 (C-5), 124.0 (C-4), 
78.4 (C-16), 57.7 (C-17), 53.4 (C-9), 52.8 (C-14), 47.9 (C-25), 45.6 (C-20), 43.6 (C-13), 39.3 (C-10), 
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38.7 (C-12), 38.5 (C-23), 35.6 (C-15), 34.9 (C-8), 34.1 (C-1), 33.9 (C-2), 32.6 (C-6), 31.7 (C-7), 23.9 
(C-24), 21.2 (16-OCOCH3), 20.6 (C-11), 17.3 (C-19), 16.3 (C-18), 13.6 (C-21), 13.3 (C-27). 
(25R)-16-Acetoxy-26-hydroxy-cholestan-3,22-dione (22). A mixture of SN-1 (20.9 mg, 0.04 mmol, 1 eq.) 
and Pd/C 10% (1.0 mg, 10% mol, 0.1 eq.) in EtOAc (5 mL) was treated with hydrogen and stirred at 
RT overnight. The reaction mixture was filtered through celite and the solvent was evaporated under 
reduced pressure. The residue was purified by chromatography on a silica gel column (hexane/EtOAc 
10:1) yielding compound 22 as a white solid (18.1 mg, 96.1%): Rf = 0.4 (hexane/AcOEt 2:1). 1H-NMR 
(CDCl3) δ: 4.83 (dd, J1 =10.7, J2 = 5.9 Hz, 1H, H-16), 3.33 (d, , 2H, H-26), 2.4 (dd, , 2H, H-24), 2.0 (s, 
3H, 28-COCH3), 1.1 (d, J = 7.1 Hz, 3H, H-21), 1.0 (s, 3H, H-19), 0.9 (s, 3H, H-18), 0.8 (d, J = 6.4 Hz, 
3H, H-27); 13C-NMR (CDCl3) δ: 212.8 (C-22), 212.1 (C-3), 170.0 (16-OCOCH3), 77.4 (C-16), 65.7 
(C-26), 56.7 (C-17), 52.2 (C-14), 51.9 (C-9), 51.7 (C-5), 46.4 (C-20), 42.6 (C-4), 42.5 (C-13), 38.4 (C-1), 
38.2 (C-12), 38.1 (C-23), 38.0 (C-2), 37.0 (C-15), 36.7 (C-10), 33.8 (C-25), 33.5 (C-8), 30.1 (C-6), 
29.6 (C-7), 25.0 (C-24), 21.2 (16-OCOCH3), 19.8 (C-19), 19.6 (C-18), 19.4 (C-11), 15.9 (C-27), 15.1 
(C-21). 
(25R)-16,26-Diacetoxy-4-cholesten-3,22-dione (23). Acetyl chloride (0.15 mL, 1.8 mmol, 450 eq.) was 
added to a mixture of SN-1 (20.1 mg, 0.04 mmol, 1 eq.) in pyridine (2 mL) and the resulting solution 
was stirred for 30 min at RT. Water was added to the reaction mixture and extracted with EtOAc  
(3 × 15 mL). The combined organic layer was washed with an aq NaHCO3 solution (30 mL), dried 
(Na2SO4) and evaporated under reduced pressure. The residue was purified by chromatography on a 
silica gel column (hexane/EtOAc, 5:2) yielding compound 23 as a white solid (22.1 mg, 100%):  
Rf = 0.6 (hexane/EtOAc 4:1). 1H-NMR (CDCl3) δ: 5.68 (s, 1H, H-4), 4.92 (dd, J1 = 10.7 Hz, J2 = 5.9 Hz, 
1H, H-16), 3.55 (d, J = 10.7 Hz, 2H, H-26), 2.4 (dd, J = 16.4 Hz, 2H, H-23), 2.0 (s, 6H, COCH3), 1.2 
(s, 3H, H-19), 1.1 (d, J = 7.1 Hz, 3H, H-21), 0.9 (s, 3H, H-18), 0.8 (d, J = 6.3 Hz, 3H, H-27).  
13C-NMR (CDCl3) δ: 212.8 (C-22), 199.4 (C-3), 171.2 (24-OCOCH3), 170.6 (16-OCOCH3), 124.0 
(C-4), 78.6 (C-16), 68.9 (C-26), 57.8 (C-17), 53.5 (C-14), 53.4 (C-9), 52.8 (C-5), 47.9 (C-20), 43.6 (C-4), 
39.3 (C-13), 39.1 (C-1), 38.5 (C-12), 35.6 (C-23), 34.9 (C-2), 34.1 (C-15), 33.9 (C-10), 32.6 (C-25), 
32.1 (C-8), 31.7 (C-6), 26.7 (C-7), 21.2 (C-24), 21.2 (16-OCOCH3), 20.8 (24-OCOCH3), 17.8 (C-19), 
15.9 (C-27), 15.1 (C-21), 13.1 (C-18). 
(25R)-16-Acetoxy-4-cholesten-3,22,26-triol (24). SN-1 (19.1 mg, 0.04 mmol, 1 eq.) in MeOH (5 mL) 
was treated with NaBH4 (38.2 mg, 1 mmol, 25 eq.) and stirred at −15 °C for 2 h and then at RT 
overnight. Water was added to the reaction mixture and extracted with DCM (2 × 15 mL). The 
combined organic layer was washed with an aq NaHCO3 solution (30 mL), dried (Na2SO4) and 
evaporated under reduced pressure. The residue was purified by chromatography on a silica gel 
column (hexane/EtOAc 1:1) yielding compound 24 as a white solid (12 mg, 63%): Rf = 0.3 
(hexane/AcOEt 1:1). M.p.: 144–146 °C. 1H-NMR (CDCl3) δ: 5.3 (d, J = 6.7 Hz, 1H, H-4), 5.0 (dt,  
J1 = 10.7 Hz, J2 = 5.9 Hz, 1H, H-16), 4.1 (q, J = 6.7 Hz, 1H, H-3,), 3.5 (tq, J = 8.0, 7.0 Hz, 2H, H-22), 
3.4 (d, J = 10.4 Hz, 2H, H-26), 2.0 (s, 3H, 16-OCOCH3), 1.2 (d, J = 7.1 Hz, 2H, H-21), 1.0 (s, 3H,  
H-19), 0.8 (s, 3H, H-18); 0.7 (d, J = 7.1 Hz, 3H, H-27); 13C-NMR (CDCl3) δ: 170.7 (16-OCOCH3), 
147.1 (C-5), 123.6 (C-4), 79.9 (C-16), 73.3 (C-22), 68.1 (C-26), 67.9 (C-3), 58.4 (C-17), 54.1 (C-9), 
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53.4 (C-14), 43.3 (C-13), 39.9 (C-12), 38.4 (C-20), 37.2 (C-10), 35.9 (C-25), 35.3 (C-8), 35.2 (C-15), 
34.3 (C-1), 32.8 (C-6), 32.0 (C-7), 31.6 (C-24), 29.9 (C-23), 29.4 (C-2), 21.4 (C-18), 21.0 (16-
OCOCH3), 20.7 (C-11), 18.8 (C-19), 16.6 (C-27), 14.2 (C-21). 
(25R)-16-Hydroxy-4-cholesten-3,22-dione-26-al (25). DMSO (0.2 mL, 2.8 mmol, 93 eq.) was added 
dropwise to a solution of (COCl)2 (0.1 mL, 2.4 mmol, 47 eq.) in DCM (5 mL) at −60 °C and the 
resulting solution was stirred for 15 min. A solution of SN-2 (21.5 mg, 0.05 mmol, 1 eq.) in DMC (3 mL) 
was added dropwise to this solution and stirred for 30 min. (iPr)2NEt (0.62 g, 4.8 mmol, 162 eq.) was 
added dropwise, and the solution was warmed at RT for 1 h. The solution was diluted with water (10 mL) 
and extracted with DMC (4 × 15 mL). The organic extracts were combined, washed with water (30 mL), 
brine (30 mL), dried over Na2SO4, and concentrated in vacuo to yield compound 25 as a white solid 
(14.9 mg, 69.8%): Rf = 0.5 (hexane/EtOAc 1:2). 1H-NMR (CDCl3) δ: 9.6 (s, 1H, CHO), 5.7 (s, 1H, 
H4), 2.9 (s, 1H, H-17), 2.6 (dd, J = 16.4 Hz, 2H, H-23), 1.1 (d, J = 7.1 Hz, 3H, H-21), 1.0 (d, J = 6.5 Hz, 
3H, H-27), 0.8 (s, 3H, H-18); 13C-NMR (CDCl3) δ: 216.8 (C-16), 213.0 (C-22), 204.4 (C-26), 199.7 
(C-3), 169.9 (C-5), 124.2 (C-4), 66.3 (C-17), 53.2 (C-9), 50.5 (C-14), 45.6 (C-25), 43.2 (C-20), 41.7 
(C-13), 39.4 (C-15), 38.9 (C-10), 38.4 (C-12), 37.1 (C-23), 35.4 (C-1), 34.6 (C-8), 33.9 (C-2), 32.5 (C-6), 
31.9 (C-7), 24.0 (C-24), 20.5 (C-11), 17.3 (C-19), 15.4 (C-18), 14.1 (C-21), 13.1 (C-27).  
3.2. Biological Assays 
3.2.1. In Vitro Antiplasmodial Activity 
A 10 mg/mL stock solution was prepared. 2.0 mg of derivatives having greater than 95% purity (as 
observed by TLC and 1H-NMR spectra) were dissolved in 200 μL pure DMSO. A 50 μL sample was 
extracted from this solution and adjusted to 1,000 μL with RPMI-1640 without hypoxanthine until a 
final 500 μg/mL concentration was reached. The P. falciparum FcB-2 (Colombia) and NF54 (The 
Netherlands) strains were used for assessing anti-malarial activity. 
Trager and Jensen’s method was used for culturing strains [24,25]. The methods described by 
Desjardins et al. [26] were used for evaluating the structural analogs’ in vitro antiplasmodial activity, 
with some modifications. 200 μL parasitized erythrocytes (1.0% parasitemia, 1.8% hematocrit) were 
placed in 96-well plates preloaded with seven concentrations (100 µg/mL–3.12 µg/mL) of each 
derivative in triplicate or with serial dilutions of chloroquine in positive control wells (3,753 nM up to  
59 nM). 1.0 µCi/mL of [3H] hypoxanthine (MP Biomedicals, Santa Ana, CA, USA) was added to each 
well and the plates were then incubated for 48 h at 37 °C in 5% CO2, 5% O2 in a balanced N2 
atmosphere. Parasite DNA was harvested and radioactivity was determined by automatic TDCR liquid 
scintillation counter plate (Chameleon, Hidex Oy, Finland). Experiments were repeated twice with two 
or three replicates each. A nonlinear regression sigmoidal dose-response (variable slope) model was 
used to estimate concentration inhibiting 50% growth (IC50) values for each derivative. 
3.2.2. Cytotoxicity 
HepG2-A16 human hepatoma cells (ATCC Hb-8065) were maintained in DMEM-F12  
(Gibco, Carlsbad, CA, USA) supplemented with 10% bovine fetal serum (BFS) (Gibco) and  
150 μg/mL penicillin/streptomycin (Sigma) at 37 °C in a 5% CO2 humidified atmosphere [27]. 
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Steroidal derivatives’ cytotoxicity regarding the HepG2-A16 cell line was evaluated by colorimetric 
test using 3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide (MTT), as described by 
Mosmann [28]. In brief, the cells were cultured in a 96-well flat-bottomed plate (2 × 105 cells/well in 
100 μL complete medium) and incubated for 24 h at 37 °C in a 5% CO2 humidified atmosphere to 
allow monolayer formation. An aliquot of each derivative dilution (100 μL, 1,000, 100, 10 and 1 μg/mL) 
was then added to the wells in triplicate. The plates were incubated for another 48 h and then 30 μL MTT 
(2 mg/mL) was added and the plates were incubated again for 4 h; DMSO (96%, 130 μL) was added 
and plates incubated for a further 20 min at RT. The DMSO diluent agent was evaluated in complete 
medium and negative controls (untreated cells) were included. Absorbance was measured at 550 nm 
and statistical Prism software version 5.0 (GraphPad Software Inc., La Jolla, CA, USA) was used for 
calculating toxic concentration (CC50). Amphotericin B was used as positive control in this assay. 
3.2.3. The in Vivo Effects of Derivatives 14 and 18 
Antimalarial activity was assessed in vivo in the P. berghei rodent malaria model according to 
Peters’ 4-day suppressive test in P. berghei-infected (ANKA strain), 5–6 week-old Balb/C mice (males 
and females) weighing 23 ± 5 g; parasitemia kinetics were evaluated following treatment [2]. The mice 
were managed according to Colombian animal protection regulations (statute 84/1989), after approval 
had been obtained from the Universidad de Antioquia’s Research Center’s (SIU) Ethics Committee. 
Assays were carried out in the SIU animal housing’s testing room, coordinated by the Tropical 
Diseases Program (PECET). The donor mice were anesthetized with a 5 mg/kg xylazine and 50 mg/kg 
ketamine cocktail; blood was then collected via intracardiac route and 100 uL of 5 × 106 P. berghei 
ANKA-parasitised parasitized erythrocytes per experimental mouse were inoculated. Mouse infection 
was checked one day later by thin smear blood test and Giemsa staining. Batches of 5 animals per 
group were then randomly distributed after infection and each group of mice received 100 μL of their 
respective treatment via oral-gastric tube (day 0) [i.e., 100 mg/kg compound 2, derivative 14, 18, 
negative control (standard suspending vehicle – SSV] or 5 mg/kg chloroquine in positive control. Mice 
were treated again with the same dose given on day 0 after 24, 48 and 72 h. Each mouse had a thin 
smear blood test on days 2, 4 and 5 (48, 96 and 120 h post-infection) and parasitemia was counted in 
10,000 red blood cells (results expressed as percentage parasitized RBC). The difference between 
control group mean value (taken as 100%) and those of the experimental groups was also calculated 
and expressed as percent reduction using the following equation: 
Inhibition = 100 − (mean percentage parasitemia treated/mean percentage parasitemia 
control with SSV) × 100) 
3.3. Computational Methods 
Each compound’s geometry was optimized by B3LYP/6-31G(d) [29], using the Gaussian 03 
software [30]. Electrostatic charges were calculated by fitting electrostatic potential to nuclear 
positions, according to the CHELPG scheme [31]. 
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3.3.1. CoMFA Details 
Steric and electrostatic 3D fields were calculated by the CoMFA method using the interaction 
between each catalyst and a probe atom. The probe atom had a specific charge and steric properties for 
evaluating interaction energy at each point on a grid. The probe atom selected was a Sp3 C atom 
having a + 1 point charge (i.e., Tripos C(3) force field atom) [32]; it was used to calculate Van der 
Waals (steric) interactions. 3D-QSAR analysis was carried out using the CoMFA module [33] and 
Sybyl 8.0 software [34]. 
3.3.2. Alignment Rule 
All structures had to be aligned in a common framework when using 3D-QSAR for comparing the 
26 compounds tested here [35]; the C atoms shared between fused A-B, B-C and C-D rings were 
selected. The best grid spacing results were obtained with a 1.0 Å lattice spacing. Such late value was 
considered an optimum value since higher precision in evaluating the 3D field by introducing a finer 
grid would have resulted in an increase of so-called “brown noise” caused by the grid size sensitivity 
of the statistical technique used for generating the models [36]. 
3.3.3. PLS Analysis 
Partial least squares (PLS) analysis was performed for different combinations of field descriptors. 
Autoscaling was used for PLS calculations regarding combined fields where each field was scaled to 
give unit value variance. Software calculated each field’s standard deviation (SD) and divided each 
value by the corresponding SD to assign the same prior importance to each variable in the analysis. 
Leave one out (LOO) [37] cross-validated PLS analysis was initially used for determining statistical 
model robustness and the optimal number of components. This involved examining the predictive 
residual sum of squares (PRESS) and using the cross-validated regression coefficient (q2) as 
guidelines. q2 was defined as: 
PRESS = 2,
1
, )( ipred
N
i
iobs YY 

 (1)
q2 = 1 − PRESS/SSD (2)
where Yobs,I and Ypred,I were actual and predicted dependent variables (respectively) and SSD the sum 
of each dependent variable’s squared deviation from the mean of all dependent variables. Some 
authors [38] have estimated that a greater than 0.3 q2 value has a 95% confidence limit. Usual drug 
design practice considers a model having a q2 greater than 0.5 to be valid, i.e., halfway between perfect 
predictions (q2 = 1.0) and no prediction at all (q2 = 0.0). The optimum number of components was 
determined by minimizing PRESS while maximizing q2 values; the model having fewer components 
was selected whenever an increase in q2 with an additional component was less than 5%. Adding more 
components improved the fitting statistics but had two disadvantages: it complicated the model and 
made it lose its predictive ability. A final model was obtained by non-cross-validated PLS analysis for 
ascertaining the optimum number of components. The experimental activity values were transformed 
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to a logarithmic scale to improve data distribution, as recommended by usual QSAR practice [12]; the 
transformation used was thus Log (1/IC50). 
4. Conclusions  
Only a few reports concerning steroids’ antiplasmodial activity could be found in the pertinent 
literature, despite the fact some steroidal alkaloids having been shown to be active against malaria.  
S. nudum steroidal compounds’ antiplasmodial activity, the good selectivity in vitro and it is well-
tolerated in early studies in a mouse model support this plant’s potential use in anti-malarial 
medication and encourage attempts to look for new pharmacophores and more active compounds than 
diosgenone. Diosgenone hemisynthesis from diosgenin is a good alternative for obtaining this 
substance when establishing its effects in an infected-mouse model and determining its in vivo activity, 
absorption and toxicity. Preparing other derivatives and synthesizing other compounds involving only 
diosgenone A- and B-rings could yield new types of antimalarial substances, even though attempting 
to obtain diosgenone from diosgenin in a single step has failed so far [21]. In short, a type of steroidal 
saponin whose bioassays in an animal model have shown promissory activity against P. falciparum 
has been reported for the first time here, though its structure should most likely be optimized to 
achieve the best pharmacokinetic properties. Such types of molecule are obtainable from a cheap, 
readily available, renewable raw material, such as diosgenin. 
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